Trials / Completed
CompletedNCT01414114
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- KAI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etelcalcetide | Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis. |
Timeline
- Start date
- 2011-12-05
- Primary completion
- 2012-05-21
- Completion
- 2012-05-21
- First posted
- 2011-08-11
- Last updated
- 2017-04-11
- Results posted
- 2017-04-11
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01414114. Inclusion in this directory is not an endorsement.